Innoviva
INVA Nasdaq· Pharmaceuticals
Last close · Oct 27, 2026
$20.94
KIRA · Stoqly’s AI analyst, in plain words
- Innoviva had $411M of revenue in fiscal 2025, up 14.7% on the year before. Over five years, revenue changed +4.1% a year on average.
- Its operating margin was 39.8%, down 6.7 pts: of every 100 in sales, about 40 is left after running the business.
- Innoviva made $271M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 22.5% a year.
- Free cash flow was $196M in fiscal 2025, 47.6% of revenue.
- Innoviva returned $4.5M to shareholders in fiscal 2025, 2% of free cash flow. The diluted share count rose 14.3%.
- Innoviva has $293M more cash than debt.
Market cap
$1.5B
P/E
5.1x
Revenue
$411M
Net income
$271M
Free cash flow
$196M
Operating margin
39.8%
Innoviva in 30 seconds · fiscal 2025
Are sales growing?
+14.7%
Yes. Sales grew 14.7% last year.
Does it make a profit?
65.9%
Yes. It keeps 65.9% of every sale as profit.
Does profit turn into cash?
47.6%
Yes. 47.6% of sales ends up as free cash.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
5.1x
One share costs 5.1 times its yearly profit per share. Typical for its sector: 28.4x.
What Innoviva does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- INNOVIVA, INC.
- CIK
- 0001080014
Innoviva · INVA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $392M | $331M | $311M | $359M | $411M |
| Revenue growth | 16.4% | −15.5% | −6.3% | 15.5% | 14.7% |
| Gross margin | — | — | 79.3% | 82.6% | 74.8% |
| Operating margin | 95.7% | — | 36.7% | 46.5% | 39.8% |
| Net income | $369M | $220M | $180M | $23.4M | $271M |
| Net margin | 94.1% | 66.5% | 57.9% | 6.5% | 65.9% |
| Diluted EPS | $2.87 | $2.37 | $2.20 | $0.36 | $3.30 |
| Cash | |||||
| Cash from operations | $364M | $202M | $141M | $189M | $197M |
| Capital expenditure | $0.0M | $0.1M | $0.4M | $0.3M | $1.1M |
| Free cash flow | $364M | $202M | $141M | $188M | $196M |
| FCF margin | 92.8% | 60.9% | 45.3% | 52.5% | 47.6% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $394M | $8.5M | $75.7M | $14.8M | $4.5M |
| Share count change | −17.0% | 1.0% | −8.8% | −14.6% | 14.3% |
| Debt and strength | |||||
| Cash and short-term investments | $202M | $291M | $194M | $305M | $551M |
| Debt incl. finance leases | $395M | $540M | $446M | $256M | $258M |
| Shareholders' equity | $415M | $566M | $675M | $691M | $1.2B |
| Net debt / EBITDA | 0.5x | — | — | — | — |
| Current ratio | 54.0x | 3.3x | 9.0x | 2.4x | 14.6x |
| Interest coverage | 19.7x | 19.2x | 5.9x | 7.5x | 9.8x |
| Returns and quality | |||||
| Return on capital | 42.4% | 30.3% | 12.1% | 13.3% | 17.9% |
| Return on equity | 77.3% | 44.9% | 29.0% | 3.4% | 29.1% |
| Piotroski F-score | 4 | 2 | 5 | 7 | 6 |
| Altman Z'' | 4.7 | 3.7 | 3.4 | 3.7 | 6.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Innoviva · INVA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Innoviva INVA | $1.5B | 14.7% | 39.8% | 47.6% | 17.9% | 5.1x | 6 |
| Amphstar Pharmaceuticals AMPH | $1.1B | −1.7% | 19.5% | 16.8% | 9.9% | 15.1x | 6 |
| Corcept Therapeutics CORT | $10.4B | 12.8% | 5.9% | 18.6% | 15.7% | — | 3 |
| Collegium Pharmaceutical COLL | $748M | 23.6% | 23.0% | 42.0% | 53.4% | 18.5x | 6 |
| ANI Pharmaceuticals ANIP | $1.6B | 43.8% | 12.6% | 19.4% | 15.9% | 15.4x | 6 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $20.94 a share, the company is worth $1.5B: 5.1 times its earnings of the last four quarters.
Innoviva grew sales faster than 2 of its 4 similar companies. Its P/E is higher than 0 of 3.
Source: SEC EDGAR XBRL filings (CIK 0001080014). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.